A recently developed tobramycin preparation for inhalation (TOBIเฎพ, Pathogenesis Corp., Seattle, WA) is widely used in CF patients. It is often used in conjunction with intravenous tobramycin. Renal and ototoxicity associated with the use of tobramycin require that serum drug concentrations be monito
Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis
โ Scribed by Maya Ramagopal; Larry C. Lands
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 60 KB
- Volume
- 29
- Category
- Article
- ISSN
- 8755-6863
No coin nor oath required. For personal study only.
โฆ Synopsis
The use of inhaled tobramycin for prophylaxis and treatment of respiratory symptoms in cystic fibrosis (CF) is now widespread. There have been concerns that inhaling the intravenous (I.V.) formulation of tobramycin causes bronchoconstriction. Previous studies using this formulation have either not specified the nebulizing equipment, or studied older, more severely affected patients. This study investigated the incidence of bronchoconstriction with tobramycin inhalation in children with mild to moderate CF. We studied 26 patients between the ages of 7 and 17 years, with mild to moderate CF (20 female). Prior to being placed on prolonged inhaled tobramycin therapy, they underwent a "tobramycin challenge." FEV(1) was measured pre and post challenge. For the test, standard I.V. solution (80 mg/2 mL) diluted with 2 mL of normal saline was nebulized, using the Hudson (Temecula, CA) RCI Updraft II nebulizer. The nebulization lasted 2 min. There was a 3-min "quiet period," following which FEV(1) was measured. A decrease in FEV(1) by at least 10% post-tobramycin inhalation was considered to be a positive test. Results were analyzed using the Pearson Chi-square test. Five of 26 (19%) had a positive reaction to tobramycin. Sixteen of 26 (61.5%) were using salbutamol on a daily basis at the time of testing but not for 48 hr before the challenge, and 16 of 26 (61.5%) had a pre-tobramycin FEV(1) of < or =80%. Neither an FEV(1) of <80% (P = 0.93) nor regular use of salbutamol (P = 0. 34) were associated with a positive tobramycin challenge. This study suggests that, while bronchoconstriction does occur, many patients do not exhibit bronchoconstriction in response to the standard I.V. preparation and, as prior work suggests, this may be reduced further by pretreatment with salbutamol.
๐ SIMILAR VOLUMES
## Abstract ## Background Though tobramycin inhalation solution has been used for over a decade to improve lung function and reduce exacerbations in patients with cystic fibrosis (CF), its effects on mortality have not been wellโdescribed. This study aimed to assess the association between use of
We compared standard chest physical therapy and postural drainage (CPT/PD) with a new airway clearance therapy called high-frequency chest wall oscillation (HFCWO) in a group of stable cystic fibrosis (CF) patients. In this crossover trial, 29 CF patients (15 males, 14 females), aged 7-47 years that
The size of bronchial mucous glands in 21 patients who presented with meconium ileus and died at less than three weeks of age were compared quantitatively with that of 28 control patients. There were no significant differences by most methods of comparison. However, pulmonary infection was seen in a